MedTech advisory boards bring together clinicians, scientists, and other experts to advise on product development, clinical strategy, market access, and commercial execution. Subject to Sunshine Act reporting and AdvaMed Code constraints. Boards bring outside experts together to give input on design, trials, reimbursement or strategy. Members are paid fair market value under written agreements with clear deliverables. Compliance teams check that meetings serve a real business need and are not disguised inducements.

Why it matters

Must be structured around legitimate need, fair-market-value compensation, and documented agendas to avoid anti-kickback risk.

Common pitfalls

•Improperly compensated advisory board members can pose a significant anti-kickback risk, leading to potential legal and financial penalties.
•Advisory boards lacking a clear, documented purpose or agenda may be viewed as a disguised inducement, rather than a legitimate scientific or business activity.
•Failing to report advisory board compensation and participants as required by regulations such as the Physician Payments Sunshine Act 42 CFR Part 403, Subpart I can result in fines and reputational damage.
•Advisory boards composed exclusively of individuals with pre-existing commercial interests, lacking diverse and independent expert perspectives, can undermine credibility.
•Using an advisory board as a sales channel, rather than a genuine forum for expert feedback, can lead to compliance violations and ethical breaches.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.